Science- The
University of Oxford team racing to find a coronavirusvaccine say it will get an early sign of whether it works on humans in mid-June. - Human trials of ChAdOx1 nCoV-19 began in Oxford on April 23, following successful tests on macaque monkeys in late March.
- "We hope to get some signal about whether it's working by the middle of June," Sir John Bell, Regius Professor of Medicine at the university, told BBC radio on Thursday.
- Bell also announced a partnership with British pharmaceutical giant AstraZeneca, which will scale up production if the vaccine is approved.
- As many as 90 vaccines are in production around the globe, a few of which have started human trials.
- Visit Business Insider's homepage for more stories.
The University of Oxford team leading the race to secure a coronavirus vaccine say it expects to get the first indication of whether it works on humans in mid-June.
Human trials of ChAdOx1 nCoV-19 began in Oxford on April 23, following successful tests on macaque monkeys in the US in late March.
"We hope to get some signal about whether it's working by the middle of June," Sir John Bell, Regius Professor of Medicine at the University of Oxford, told the BBC's "Today" radio program on Thursday.
"This is still a development program."
The vaccine is being developed in the main by the Jenner Institute, an independent research group working as part of the Oxford Vaccine Group.
About 1,100 people are expected to be injected as part of the UK government-funded trial.
As many as 90 vaccines are in development around the globe, but early indications suggest that the Oxford group is leading the way.
Vaccines usually take between five and ten years to develop, test, approve, regulate, and licence but the
Early readouts of Oxford's human trials will become available to Andrew Pollard, the head of the clinical trial program, in May.
Also on Thursday, the Oxford Vaccine Group announced a partnership with British pharmaceutical giant AstraZeneca to help scale up production when human trials conclude.
"We wil need to make 30 or 40 million doses in the first instance to get enough available. If it gets approved we can vaccinate people immediately," Bell told the BBC.
However, he noted there were several challenges to navigate even if their vaccine gets approved.
"The vials that you put the vaccine in, the so called fill-and-finish, there's ony 200 million vials left in the world now because they've all been sucked up by various people who can anticipate a vaccine coming along," he said. "There's lots of challenges."
Professor Sarah Gilbert, a leading expert in the Oxford Vaccine Group, initially set September as the date when it would know if the vaccine works for certain.
However, last week the world's largest vaccine maker, The Serum Institute of India, said it wouldn't wait that long, and began developing millions of batches of ChAdOx1 nCoV-19 right away.
"We are not waiting for the trials to get over in September in UK, and then start production here," Adar Poonawalla, the CEO of the Institute, said.
"The decision — at our own risk and cost — has been solely taken to get a jump-start on manufacturing, to have enough doses available, if the clinical trials prove successful."
A number of other vaccines in development have also reached human trials, as Business Insider's Mia Jankowicz previously reported.
The US and German pharmaceutical companies Pfizer and BioNTech recently injected 12 healthy people in Germany with their experimental BNT162 vaccine.
Moderna, the US biotech company, is also conducting human trials, and has submitted a new drug application for its mRNA-1273 vaccine to the US Food and Drug Administration.
GlaxoSmithKline, one of the world's biggest vaccine manufacturers, is also with the French pharmaceutical company Sanofi on a vaccine. They say it will be ready for human testing in the second half of 2020.
Some scientists worry that a vaccine may never emerge. So far, no vaccines exist for any of the major coronaviruses.
Read the original article on Business Insider